Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press36010.17650/1726-9776-2012-8-4-48-52PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫMOLECULAR MARKERS FOR METASTATIC PROSTATE ADENOCARCINOMAМОЛЕКУЛЯРНЫЕ МАРКЕРЫ МЕТАСТАЗИРОВАНИЯ АДЕНОКАРЦИНОМЫ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫKuninI. S.КунинИ. С.
Russian Federation
I.S.Kunin@ngs.ruBoboevM. M.БобоевМ. М.
Russian Federation
I.S.Kunin@ngs.ruKutsenkoO. S.КуценкоО. С.
Russian Federation
I.S.Kunin@ngs.ruMostovichL. A.МостовичЛ. А.
Russian Federation
I.S.Kunin@ngs.ruAidagulovaS. V.АйдагуловаС. В.
Russian Federation
I.S.Kunin@ngs.ruGrigorievaE. V.ГригорьеваЭ. В.
Russian Federation
I.S.Kunin@ngs.ruNovosibirsk state medical universityГБОУ ВПО Новосибирский ГМУ Минздрава РоссииNovosibirsk regional clinicsНовосибирская областная клиническая больницаInstitute of molecular biology and biophysics, Siberian Division of RAMS, NovosibirskФГБУ НИИ молекулярной биологии и биофизики СО РАМН, Новосибирск301220128448520708201407082014https://oncourology.abvpress.ru/oncur/article/view/360

The search of molecular markers of metastasing and prognosis in prostate cancer remains an urgent task. In this study, we investigated the relationship of gene expression heparanase-1 (HPSE1) and D-glucuronil C5-epimerase (GLCE) with early disease relapse and metastasis of a 2,5−3 years after diagnosis. It was shown that the ratio of the expression levels of genes HPSE1/GLCE > 1 may serve as a prognostic relapse marker and trends of the tumour to metastasis. The data obtained suggest to use this option as a molecular marker for the diagnostics of metastatic process and the disease prognosis.

Поиск молекулярных маркеров метастазирования и прогноза при раке предстательной железы остается актуальной задачей. В данной работе изучена взаимосвязь экспрессии генов гепараназы-1 (HPSE1) и Д-глюкуронил С5-эпимеразы (GLCE) с ранним рецидивом заболевания и метастазированием через 2,5−3 года после постановки диагноза. Показано, что отношение уровней экспрессии генов HPSE1/GLCE > 1 может служить прогностическим маркером рецидива заболевания и тенденции опухоли к метастазированию. Полученные данные позволяют предложить использовать этот параметр как молекулярный маркер для диагностики метастатического процесса и оценки прогноза течения заболевания.

prostate adenocarcinomamolecular markers for prostate cancer metastasisheparanase-1D-glucuronyl C5-epimeraseаденокарцинома предстательной железымолекулярные маркеры метастазированиягепараназа-1Д-глюкуронил С5-эпимераза1. Madu C.O., Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010; 1:150−77.Madu C.O., Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010; 1:150−77.2. Bjartell A., Montironi R., Berney D.M., Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011;50 (Suppl 1):76−84.Bjartell A., Montironi R., Berney D.M., Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011;50 (Suppl 1):76−84.3. Schroder F.H. Review of diagnostic markers for prostate cancer. Recent Results. Cancer Res 2009;181:173−82.Schroder F.H. Review of diagnostic markers for prostate cancer. Recent Results. Cancer Res 2009;181:173−82.4. Shariat S.F., Scherr D.S., Gupta A. et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol 2011;64(8):681−94.Shariat S.F., Scherr D.S., Gupta A. et al. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch Esp Urol 2011;64(8):681−94.5. Reed A.B., Parekh D.J. Biomarkers for prostate cancer detection. Expert Rev Anticancer Ther 2010;10(1):103−14.Reed A.B., Parekh D.J. Biomarkers for prostate cancer detection. Expert Rev Anticancer Ther 2010;10(1):103−14.6. Zhong W.D., Han Z.D., He H.C. et al. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 2008;75(3−4):230−6.Zhong W.D., Han Z.D., He H.C. et al. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 2008;75(3−4):230−6.7. Szarvas T., Becker M., Vom D.F. et al. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer 2011;128(6): 1486−92.Szarvas T., Becker M., Vom D.F. et al. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer 2011;128(6): 1486−92.8. Edwards I.J. Proteoglycans in prostate cancer. Nat Rev Urol 2012;9(4):196−206.Edwards I.J. Proteoglycans in prostate cancer. Nat Rev Urol 2012;9(4):196−206.9. Levy-Adam F., Ilan N., Vlodavsky I. Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 2010; 20(3):153−60.Levy-Adam F., Ilan N., Vlodavsky I. Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 2010; 20(3):153−60.10. Parish C.R., Freeman C., Hulett M.D. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471(3):M99−108.Parish C.R., Freeman C., Hulett M.D. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471(3):M99−108.11. Vlodavsky I., Beckhove P., Lerner I. et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012; 5(2):115−32.Vlodavsky I., Beckhove P., Lerner I. et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012; 5(2):115−32.12. Kutsenko O.S., Kovner A.V., Mostovich L.A. et al. Expression of heparanase-1 in prostate gland tumors. Bull Exp Biol Med 2012;152(3):344−7.Kutsenko O.S., Kovner A.V., Mostovich L.A. et al. Expression of heparanase-1 in prostate gland tumors. Bull Exp Biol Med 2012;152(3):344−7.13. Miao H.Q., Liu H., Navarro E. et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006; 13(18):2101−11.Miao H.Q., Liu H., Navarro E. et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006; 13(18):2101−11.14. Liu C.J., Lee P.H., Lin D.Y. et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50(5):58−68.Liu C.J., Lee P.H., Lin D.Y. et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50(5):58−68.15. Martin S.K., Vaughan T.B., Atkinson T. et al. Emerging biomarkers of prostate cancer. Oncol Rep 2012;28(2):409−17.Martin S.K., Vaughan T.B., Atkinson T. et al. Emerging biomarkers of prostate cancer. Oncol Rep 2012;28(2):409−17.16. Li J.P. Glucuronyl C5-epimerase an enzyme converting glucuronic acid to iduronic acid in heparan sulfate/heparin biosynthesis. Prog Mol Biol Transl Sci 2010;93:59−78.Li J.P. Glucuronyl C5-epimerase an enzyme converting glucuronic acid to iduronic acid in heparan sulfate/heparin biosynthesis. Prog Mol Biol Transl Sci 2010;93:59−78.17. Prudnikova T.Y., Mostovich L.A., Domanitskaya N.V. et al. Antiproliferative effect of D-glucuronyl C5-epimerase in human breast cancer cells. Cancer Cell Int 2010;10:27.Prudnikova T.Y., Mostovich L.A., Domanitskaya N.V. et al. Antiproliferative effect of D-glucuronyl C5-epimerase in human breast cancer cells. Cancer Cell Int 2010;10:27.18. Grigorieva E.V., Prudnikova T.Y., Domanitskaya N.V. et al. D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo. Br J Cancer 2011;105(1):74−82.Grigorieva E.V., Prudnikova T.Y., Domanitskaya N.V. et al. D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo. Br J Cancer 2011;105(1):74−82.19. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 2011;15(5):1013−31.Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 2011;15(5):1013−31.